Insilico Medicine Company
Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.
Investors
Technology:
Artificial Intelligence, Biotechnology, Genetics, Health Care, Pharmaceutical
Industry:
AI, End-to-end Drug Development
Headquarters:
Hong Kong, Hong Kong Island, Hong Kong
Zip:
101-250
Founded Date:
2014-01-01
Employees Number:
101-250
Funding Status:
Late Stage Venture
Acquisitions Number:
31
Investors Number:
32
Total Funding:
401300000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2022-08-10
Last Funding Type:
Series D
Register and Claim Ownership